Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics director Timothy L. Main reported a small acquisition of 21 shares of common stock on 2026-07-22 at $206.81 per share. The shares were acquired through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, though he chose to report early. After this transaction, he directly holds 22,460 shares and indirectly holds 5,000 shares through a trust.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 102 shares of Quest Diagnostics common stock on July 22, 2026, at $206.807 per share in a grant/award transaction, bringing his directly held position to 33,478 shares.
Footnotes state the security represents an award of restricted share units and that the shares were acquired through a dividend reinvestment plan administered by his broker, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was voluntarily reported early.
Quest Diagnostics Inc. director Wright Lassiter III reported a small acquisition of common stock. On 2026-07-22, he acquired 6 shares at $206.813 per share through a dividend reinvestment plan administered by his broker, increasing his direct holdings to 10,323 shares. The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report it early on Form 4. The Rule 10b5-1 checkbox was not marked as a trading plan.
Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported a small acquisition of 34.0000 shares of common stock on 2026-07-22 at 206.8070 per share through a broker-administered dividend reinvestment plan, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was reported early. Following this transaction, his direct holdings total 11935.0000 shares. A footnote notes that the security is described as common stock but represents an award of restricted share units.
Quest Diagnostics reported strong Q2 2026 results, with net revenues of $3,043 million, up 10.2% from 2025, driven mainly by its Diagnostic Information Services business. DIS volume rose 13.1% (13.0% organic), helped by new relationships with Corewell Health and Fresenius Medical Care, while revenue per requisition declined 2.8% due to a higher mix of routine tests.
Net income attributable to Quest Diagnostics increased to $320 million and diluted EPS to $2.84 for the quarter; for the first half of 2026, net revenues were $5,938 million and diluted EPS $5.08. Operating margins remained in the mid-teens as higher compensation and supply costs were partially offset by the multi‑year Invigorate cost‑savings program. Cash generated from operating activities reached $875 million in the first half against capital expenditures of $252 million. The company ended June 30, 2026 with $626 million in cash and $5,642 million of long‑term debt after issuing $500 million of 5.00% senior notes due 2036 and repaying $500 million of 3.45% notes, and continued returning capital through $0.86 quarterly dividends and $100 million of share repurchases.
Quest Diagnostics reported strong second-quarter 2026 results. Net revenues were $3.04 billion, up 10.2% year over year, including 10.0% organic revenue growth and a 13.1% increase in requisition volume, while revenue per requisition declined.
Reported diluted EPS rose 15.0% to $2.84, and adjusted diluted EPS increased 19.1% to $3.12. For the first six months of 2026, net revenues were $5,938 million and diluted EPS was $5.08. Operating cash flow reached $875 million, funding $252 million of capital expenditures and $100 million of share repurchases, as cash and equivalents increased to $626 million.
The company raised full‑year 2026 guidance, now expecting net revenues of $11.95–$12.05 billion, reported diluted EPS of $9.97–$10.17, and adjusted diluted EPS of $11.05–$11.25. Expected cash from operations was increased to approximately $1.80 billion, with capital spending still projected at about $550 million.
Quest Diagnostics director Timothy C. Wentworth reported a routine compensation-related transaction involving deferred equity-based awards. He received 144 Phantom Stock Units, representing an elective deferral of his director cash compensation under the company’s Amended and Restated Deferred Compensation Plan for Directors. Each unit is tied to Quest Diagnostics common stock and is payable in cash when his service as a director ends. Following this grant, he holds 342 Phantom Stock Units in total. This filing reflects a non-cash grant/award acquisition rather than an open-market stock purchase or sale.
Quest Diagnostics senior vice president Karthik Kuppusamy exercised stock options and sold shares in a pre-planned trade. On 2026-06-04, he exercised options for 4,827 shares at $121.805 per share and 3,320 shares at $127.725, acquiring 8,147 shares of common stock through derivative exercises.
That same day, he completed an open-market sale of 8,147 common shares at $200.00 per share pursuant to a Rule 10b5-1 sales plan, converting option value into cash in a pre-arranged manner. Following these transactions, he directly held 13,510 common shares, with additional indirect holdings of 358 shares in a trust and 1,721 shares through the company’s 401(k) profit sharing plan.
Quest Diagnostics CEO and President J. E. Davis reported an open-market sale of 10,000 shares of Common Stock on June 1, 2026 at a price of $194.14 per share.
After this transaction, Davis directly holds 132,423 shares of Quest Diagnostics Common Stock. The sale was carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person, indicating it was scheduled in advance rather than timed discretionarily.